# Merck Acquires Silence Therapeutics

> Merck buys Silence Therapeutics for $1.3 billion to boost rare disease treatments.
- Title: Merck Acquires Silence Therapeutics · Pulse 2.0 | Shortify
- Summary: Merck buys Silence Therapeutics for $1.3 billion to boost rare disease treatments. Merck acquires Silence Therapeutics for $1.3 billion to advance rare…
- Keywords: merck, silence therapeutics, sirna, polycythemia vera, phase 2, acquisition, rare diseases, startups, business, Acquires, Silence, Therapeutics
- Source: Pulse 2.0 — https://pulse2.com/merck-to-acquire-silence-therapeutics-for-about-1-3-billion
- Author: Amit Chowdhry
- Published: 2026-10-19T13:21:20+00:00
- Read time: 1 min
- Topics: merck, silence therapeutics, sirna, polycythemia vera, phase 2, acquisition, rare diseases, startups, business
## Merck Acquires Silence Therapeutics
Merck has agreed to buy Silence Therapeutics for about $1.3 billion in an all-cash transaction.
## Shareholder Deal Details
Silence shareholders receive $20.00 per American Depositary Share, equivalent to $6.6667 per ordinary share.
## Premium Over Market
The deal offers a 130% premium to Silence’s ADS closing price on October 16, 2026, and an 82% premium to its 30-day volume-weighted average price.
## Divesiran Phase 2 Data
Silence’s Divesiran shows potentially best-in-class results for polycythemia vera in Phase 2 trials.
## Merck’s Strategy
Merck aims to expand in rare diseases using external innovation to strengthen its pharmaceutical pipeline.
## Key takeaway

Merck acquires Silence Therapeutics for $1.3 billion to advance rare disease therapies using siRNA technology.